Ido1 and Ido2 deficiencies attenuate kainic acid-induced ictogenesis.

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Brain insults like injury, infection, or chemical exposure can trigger seizures (ictogenesis).
• The acute ictogenic period is a critical window for intervention, as it increases the risk of developing treatment-resistant epilepsy.
• Indoleamine-2,3-dioxygenases (Ido1 and Ido2) are enzymes that modulate neuroprotective and inflammatory responses.

Purpose of the Study:

• To investigate the role of Ido1 and Ido2 in kainic acid (KA)-induced seizures.
• To determine the impact of global and cell-type-specific Ido1 and Ido2 deficiencies on ictogenesis.
• To explore the potential of peripheral Ido1 and Ido2 as targets for anti-seizure drug discovery.

Main Methods:

• Utilized Ido1 knockout (Ido1-/-) and Ido2 knockout (Ido2-/-) mice.
• Administered kainic acid (KA) intraperitoneally to induce seizures.
• Assessed seizure incidence, hyperlocomotion, and hippocampal cytokine expression.
• Generated mice with cell-type-specific Ido1 and Ido2 deficiencies in neurons, astrocytes, myeloid-derived cells, and microglia.

Main Results:

• Global Ido1-/- and Ido2-/- mice exhibited reduced seizure incidence and hyperlocomotion after KA treatment compared to wild-type controls.
• KA treatment did not alter Ido1 or Ido2 expression or hippocampal cytokine levels across genotypes.
• Cell-type-specific deficiencies demonstrated that Ido1 or Ido2 loss in neurons, astrocytes, and myeloid cells increased ictogenesis.
• Microglial Ido2 deficiency, but not Ido1, also enhanced ictogenesis.

Conclusions:

• The role of Ido1 and Ido2 in ictogenesis is cell-type-dependent, with distinct functions in global knockouts versus specific cell populations.
• Neurons, astrocytes, microglia, and macrophages appear to utilize Ido1 and Ido2 for protection against seizures.
• Conversely, Ido1 or Ido2 in other brain or peripheral cells may promote ictogenesis.
• Peripheral Ido1 and Ido2 represent potential targets for novel anti-seizure therapies, warranting careful consideration of cell-specific contributions.